In 2022, the human respiratory syncytial virus (RSV) treatment market is anticipated to be worth US$ 1,533.74 million in terms of revenue. The market is projected to expand at a CAGR of 11% to reach a market size of US$ 4,354.93 million by 2032.
| Attributes | Details |
|---|---|
| Human Respiratory Syncytial Virus (RSV) Treatment Market CAGR | 11% |
| Human Respiratory Syncytial Virus (RSV) Treatment Market (2022) | US$ 1,533.74 Million |
| Human Respiratory Syncytial Virus (RSV) Treatment Market (2032) | US$ 4,354.93 Million |
A syncytial virus is a multi-nucleated virus which results from multiple cell fusions. Human respiratory syncytial virus (RSV) has a size of around 120 to 200 nm and is an enveloped virus with a linear minus-sense RNA genome.
Human respiratory syncytial virus (RSV) causes complications such as bronchiolitis, asthma, chronic respiratory tract infections and acute otitis media in patients. Human respiratory syncytial virus (RSV) infects the lungs and breathing passages. Human respiratory syncytial virus (RSV) infection is experienced as a mild cold in healthy individuals while it can cause serious complications in infants and children younger than one year.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global spread of the human respiratory syncytial virus (RSV) is encouraging market expansion. One of the most common causes of lower respiratory tract infections in newborns and young children is the respiratory syncytial virus.
Respiratory syncytial is the second leading cause of mortality in infants under the age of one, according to the World Health Organization (WHO). This can be related to the fact that there are fewer treatment choices accessible to prevent or treat the illness, which is anticipated to fuel market expansion.
As more breakthrough products are approved to meet this need, the human respiratory syncytial virus (RSV) treatment is expected to rise at a significant rate throughout the projected period. The human respiratory syncytial virus treatment market is expected to develop as a result of growing awareness of the disease, the rising importance of early diagnosis, and increasing spending on chronic illnesses.
Government funding for RSV treatment is growing, and proactive government initiatives are creating beneficial prospects. The World Health Organization has begun the BRaVe (Battle Against Respiratory Viruses) campaign, which aims to lessen the public health (severe disease) and financial impact of viral respiratory infections by addressing knowledge gaps, creating novel therapeutic and preventive interventions, and proposing comprehensive strategies that take viral etiologies into account.
The list of preclinical vaccine developers also includes governmental organizations and pharmaceutical companies. Hence, the human respiratory syncytial virus treatment market is also expected to expand at a profitable rate as a consequence of government support and investment.
Nasal suctions and lubrications are provided for nasal congestion. Antipyretics are given for fever and oxygen and hydration management are all part of the supportive care approach for treating RSV. As supportive care is the major treatment for the respiratory syncytial virus and the condition is highly frequent in children under the age of two, this is causing the market to develop.
Top competitors in the human respiratory syncytial virus treatment market are concentrating on creating solutions that are both affordable and of a high caliber to take advantage of the enormous untapped prospects in developing nations. This is evident from the rising R&D expenditures and the rising number of new product approvals.
A deeper understanding of RSV biology by the service providers for the creation of medicines and vaccines to treat, cure, and prevent the virus as a result of technological advancements, is anticipated to fuel market expansion. Manufacturers are developing medications and vaccines with reduced drug toxicity and improved efficacy, which is anticipated to have a beneficial influence on the expansion of the human respiratory syncytial virus (RSV) treatment market throughout the forecast period.
The growing usage of pharmaceuticals by kids for sickness prevention and treatment is expected to drive growth in the worldwide RSV treatment market. Furthermore, it is anticipated that numerous companies would develop treatments that are reasonably priced to treat RSV sickness, increasing demand globally and fostering growth.
For instance, in August 2020 Janssen Pharmaceutical Companies, a part of Johnson and Johnson Service, Inc., reported that the US FDA had granted their RSV preventive vaccination a breakthrough certification. The certification was made using clinical evidence from Janssen's preventative RSV senior vaccination, which might potentially be better than the current standard of therapy.
Principal Consultant
Human respiratory syncytial virus (RSV) is a syncytial virus which causes respiratory tract infections, particularly the lower respiratory tract infections in infants and children. The prophylaxis for Human respiratory syncytial virus (RSV) treatment is in the form of medications.
Infants and children become weak after recovery and continue to spread the virus for the next one to three weeks. The Human respiratory syncytial virus (RSV) infection can infect people of any ages but the severity is low in adults while infants and children with weakened immune systems show high severity of the infection.
The growing number of patient cases is expected to drive the market growth while the lack of appropriate in-vitro facilities for conducting research studies for newer treatment alternatives is projected to hamper the market growth with a high impact over 2026.
As per the World Health Organization statistics, Human respiratory syncytial virus (RSV) causes 64 Mn infections and 160,000 deaths annually. Natural infection with Human respiratory syncytial virus (RSV) induces immunity against the virus which decreases over time. Human respiratory syncytial virus (RSV) infections are recurrent.
Currently, Human respiratory syncytial virus (RSV) infection lacks an approved vaccine therapy owing to limited number of studies in vitro and inability to culture the virus and maintain it in a stable state. As a result, the global Human respiratory syncytial virus (RSV) market is anticipated to grow at a moderate CAGR during the forecast period from 2016 to 2026.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Depending on geographic regions, global radiofrequency ablation system market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. According to the statistics of U.S.
Department of Health & Human Services, it is estimated that more than half the total children population globally get infected with Human respiratory syncytial virus (RSV) within the first two years of birth.
Owing to the viral infection outbreaks in winter and spring in North America, the diagnosis by a physical examination, chest x-rays to check for bronchiolitis, skin monitoring, blood tests for white cell counts and other laboratory tests for checking the respiratory secretions and treatment of the viral infection through medications is expected to drive market growth in the region through the forecast period and contribute significantly to the global market.
Some of the key market players identified in global Human Respiratory Syncytial Virus (RSV) Treatment Market are AstraZeneca, Arrow Therapeutics, Alnylam to name a few.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, accessories and applications.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Human Respiratory Syncytial Virus (RSV) Treatment Market is classified on the basis of treatment, end use and geography.
Healthcare
January 2023
REP-GB-2345
250 pages
Explore Healthcare Insights
View Reports
Human Respiratory Syncytial Virus (RSV) Treatment Market
